6-Feb-2023

Dexmedetomidine: Increased risk of mortality in intensive care unit (ICU) patients \( \leq 63.7 \) years

Dear Healthcare professional,

Risk of mortality: Use of dexmedetomidine for longer than 24 hours has been associated with an increased mortality in critically ill adult ICU patients 63.7 years of age and younger compared to usual care

Teva, the sponsor of Dexmedetomidine-Teva Concentrate for infusion, would like to inform you of the following:


Summary

- The SPICE III study was a randomised clinical trial comparing the effect of sedation with dexmedetomidine on all-cause mortality with the effect of “usual standard of care” in 3904 ventilated critically ill adult intensive care unit (ICU) patients.

- Dexmedetomidine was associated with an increased risk of mortality in the age group \( \leq 63.7 \) years compared with alternative sedatives (odds ratio 1.26; 95% credibility interval 1.02 to 1.56).

- This heterogeneity of effect on mortality from age was most prominent in patients admitted for reasons other than post-operative care, and increased with increasing APACHE II scores and with decreasing age. The mechanism is not known.

- These findings should be weighed against the expected clinical benefit of dexmedetomidine compared to alternative sedatives in younger patients.

- The product information of dexmedetomidine containing products is being updated with a warning statement describing the evidence, and risk factors, for increased risk of mortality in ICU patients \( \leq 63.7 \) years of age.

Background on the safety concern

Dexmedetomidine containing products are indicated for:

- ICU Sedation
  For sedation of initially intubated patients during treatment in an intensive care setting. The use of Dexmedetomidine-Teva by continuous infusion in these patients should not exceed 24 hours.

- Procedural Sedation
  For sedation of non-intubated patients prior to and/or during surgical and other procedures.
The academia-sponsored SPICE III trial enrolled 4000 ICU patients needing mechanical ventilation, who were randomly allocated to receive sedation with either dexmedetomidine as primary sedative or with standard of care (propofol, midazolam). Although the target sedation range was light sedation (RASS -2 to +1), deeper sedation levels (RASS -4 and -5) were also allowed. The administration of dexmedetomidine was continued as clinically required for up to 28 days after randomization.\(^1\)

Altogether, 3904 patients were included in an intention-to-treat analysis. Results are shown in Table 1 below. The study showed no difference in 90-day mortality overall between the dexmedetomidine and the usual care group (propofol, midazolam). The median age of patients included in the analysis was 63.7 years.\(^1\)

In subsequent analyses, a heterogeneity of treatment effect of dexmedetomidine has been identified.\(^2\) An increased risk of 90-day mortality (odds ratio 1.26 [95% CI 1.02-1.56]) was observed among patients ≤ 63.7 years of age. While the mechanism is yet unclear, the heterogeneity of effect on mortality from age was most prominent in patients admitted for other reasons than post-operative care, and increased with increasing APACHE II scores and with decreasing age.

Table 1: 90-days mortality

<table>
<thead>
<tr>
<th>Subgroup per age</th>
<th>Dexmedetomidine n/total (%)</th>
<th>Usual care n/total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>566/1948 (29.1)</td>
<td>569/1956 (29.1)</td>
</tr>
<tr>
<td>≤ median age 63.7 years</td>
<td>219/976 (22.4)</td>
<td>176/975 (18.1)</td>
</tr>
<tr>
<td>&gt; median age 63.7 years</td>
<td>347/972 (35.7)</td>
<td>393/981 (40.1)</td>
</tr>
</tbody>
</table>

The product information of dexmedetomidine containing products is being updated with a warning statement describing increased risk of mortality in ICU patients ≤63.7 years of age.

**Call for reporting**

Reporting suspected adverse reactions is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse events at https://nzphvc.otago.ac.nz/reporting/.

**Company contact point**

For safety related inquiries: Safety.Australia@tevapharm.com

For medical inquiries: MedInfo.ANZ@tevapharm.com

Tel: 0800 800 097

**References**